# RAMP 201

Source: https://onco.cc/trials/ramp-201/  
OnCo record `ramp-201` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RAMP 201 produced the first approved treatment designed for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway that shrugs off chemotherapy.

## Summary

In KRAS-mutant tumours, the confirmed response rate was 44% with median PFS 19.6 months and median duration of response 31.1 months; response was lower in KRAS-wild-type disease (Targeted Oncology, 2025). FDA accelerated approval 8 May 2025 for KRAS-mutated recurrent LGSOC after prior systemic therapy. The confirmatory RAMP 301 phase 3 versus chemotherapy or endocrine therapy is ongoing.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT04625270
- Phase: 2
- Setting: Recurrent low-grade serous ovarian cancer: avutometinib (RAF/MEK clamp) + defactinib (FAK inhibitor)
- Sponsor: Verastem
- Result: ORR 44%, median PFS 19.6 months in KRAS-mutant LGSOC.
- Outcomes: Objective response rate (KRAS-mutant): Avutometinib + defactinib 44%; Progression-free survival (KRAS-mutant): Avutometinib + defactinib 19.6 months

## Sources

- ClinicalTrials.gov NCT04625270: https://clinicaltrials.gov/study/NCT04625270
- MSK on approval: https://www.mskcc.org/news/fda-approves-avutometinib-defactinib-combination-for-treating-recurrent-low-grade-serous-ovarian-cancer-with-kras-mutation

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Avutometinib + defactinib](https://onco.cc/drugs/avutometinib-defactinib/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- terms: [Low-grade serous ovarian cancer (LGSOC)](https://onco.cc/terms/lgsoc/)
- key papers: [RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer](https://onco.cc/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/)

---
JSON: https://onco.cc/api/v1/entities/ramp-201.json